The synthesis of novel4-(phenylethynyl)pyridinesubunits containing H2O-soluble complexing agents and their luminescence with EuIII ions are reported. Ligands with high luminescence intensities as well as quantum yields were obtained. Also the prepared labeling reagents as antibody conjugates gave the highest quantum and luminescence yields reported for H2O-soluble EuIII labels.
The carborane framework gives analogues able to induce20Sproteasomeactivities. A series of ortho‐carboranylphenoxy derivatives were synthesized as 20Sproteasome agonists, and carborane derivatives 11 a and 11 b were found to be potent inducers of the β1 and β2 activities of the 20Sproteasome. Since small‐molecule proteasome activators have not been developed, the carboranes described here have
A series of boron-containing phenoxyacetanilide derivatives 8a-f, 9a-f, 15, and 16 were synthesized as hypoxia-inducible factor (HIF)-1 alpha inhibitors. Among the compounds synthesized, carboranylphenoxy-acetanilide 16 (GN26361) was found to be a potent inhibitor against HIF-1 alpha accumulation under hypoxic conditions and inhibited the hypoxia-induced HIF-1 transcriptional activity in HeLa cells (IC50 = 0.74 mu M). Compound 16 suppressed hypoxia-induced HIF-1 alpha accumulation and vascular endothelial growth factor mRNA expression in a concentration-dependent manner without affecting the expression of HIF-1 alpha mRNA. (C) 2009 Elsevier Ltd. All rights reserved.
Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA<sub>1</sub>/GPR40), a Potential Target for the Treatment of Type II Diabetes
作者:Elisabeth Christiansen、Christian Urban、Nicole Merten、Kathrin Liebscher、Kasper K. Karlsen、Alexandra Hamacher、Andreas Spinrath、Andrew D. Bond、Christel Drewke、Susanne Ullrich、Matthias U. Kassack、Evi Kostenis、Trond Ulven
DOI:10.1021/jm8010178
日期:2008.11.27
A series of 4-phenethynyldihydrocinnamic acid agonists of the free fatty acid receptor 1 (FFA(1)) has been discovered and explored. The preferred compound 20 (TUG-424, EC50 = 32 nM) significantly increased glucose-stimulated insulin secretion at 100 nM and may serve to explore the role of FFA(1) in metabolic diseases such as diabetes or obesity.